Travere Therapeutics Announces Topline Results from

The DUPLEX Study did not achieve the primary efficacy eGFR slope endpoint over 108 weeks of treatment Secondary and topline exploratory endpoints trended...

Related Keywords

United States ,Deric Dube ,Jula Inrig ,Nivi Nehra ,Naomi Eichenbaum ,Corporate Communications ,European Union ,Travere Therapeutics Inc ,Nasdaq ,Exchange Commission On ,Company Annual Report On Form ,European Medicines Agency ,Travere Therapeutics ,Dual Endothelin Angiotensin Receptor Antagonist ,New Drug Application ,Conditional Marketing Authorization ,Efficacy Endpoints ,Two Year Exploratory Endpoints ,Important Safety ,Endothelin Receptor Antagonists ,Upper Limit ,Fetal Toxicity ,Kidney Injury ,Angiotensin System ,Acid Reducing Agents ,Steroidal Anti Inflammatory Agents ,Including Selective ,Increasing Serum Potassium ,Reproductive Potential ,Full Prescribing Information ,Private Securities Litigation Reform Act ,Annual Report ,Exchange Commission ,Nasdaq Tvtx ,Nc ,Gravere ,Rvtx ,